The difference in all-cause mortality between COVID-19 patients treated with standard of care plus placebo and those treated with standard of care alone: a network meta-analysis of randomised controlled trials of immunomodulatory kinase inhibitors.
Ping-Tao TsengBing-Syuan ZengChih-Wei HsuTrevor ThompsonBrendon StubbsPo-Ren HsuehKuan-Pin SuYen-Wen ChenTien-Yu ChenYi-Cheng WuPao-Yen LinAndre F CarvalhoDian-Jeng LiTa-Chuan YehCheuk-Kwan SunYu-Shian ChengYow-Ling ShiueChih-Sung LiangYu-Kang TuPublished in: Journal of the Royal Society of Medicine (2023)
The current study was approved by the Institutional Review Board of the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (TSGHIRB No. B-109-29) and registered in PROSPERO (CRD42022376217).